Key result
Pharmacovigilance analyses and datamining from extensive databases have enabled the identification and understanding of new cardiovascular adverse drug reactions related to cancer treatments.
Why the study?
Cardio-oncology aims to prevent and treat cardiovascular toxicities related to cancer treatments, but understanding and managing these toxicities requires multidisciplinary approaches including pharmacovigilance.
Highlights the importance of a multidisciplinary cardio-onco-pharmacology approach utilizing pharmacovigilance to understand and manage cardiovascular toxicities from cancer treatments.
May aid cardio-oncology signal detection via pharmacovigilance; leaves open need for prospective validation before practice change.
Cardio-oncology is an emerging field that transformed the medical management of patients with cancer. It encompasses the prevention and treatment of cardiovascular toxicities related to cancer treatments, aiming to reduce cardiac adverse events among cancer survivors. Cardiovascular toxicities related to cancer treatments are described through data collected during phase I to phase III therapeutic trials, and post-marketing surveillance (phase IV). Pharmacovigilance analyses, based on datamining from these extensive databases, allowed to understanding and identifying new adverse drug reactions, some recently made available, such as immunotherapy or inhibitor of Bruton tyrosine kinase (IBTK).
No takes yet. Share an insight, caveat, or question.
Éderhy et al. (2021) conducted a review in Cardiovascular toxicities related to cancer treatments. Cancer treatments was evaluated. Pharmacovigilance analyses and datamining from extensive databases have enabled the identification and understanding of new cardiovascular adverse drug reactions related to cancer treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: